Posted by Michael Wonder on 01 Mar 2016
EUSA Pharma and AVEO announce submission of marketing authorization application for tivozanib in advanced renal cell carcinoma
1 March 2016 - EUSA Pharma and AVEO Oncology today announced the submission of a marketing authorization application to the EMA for tivozanib for the first-line treatment of advanced renal cell carcinoma.
For more details, go to: http://www.eusapharma.com
